



## TABLE OF CONTENTS

Conducting a Search .....	2
Advancing Your Search.....	3
Reading Your Search Results.....	4
Modifying Your Search.....	5
Selecting a Study.....	6
Study Record Page.....	7
Study Contacts and Site Locations .....	9
Study Participation Criteria ....	10
Study Plan.....	12
Collaborators and Investigators .....	13
Publications .....	14
Study Record Dates .....	15
More Information.....	16

## How to Use ClinicalTrials.gov

If you are a patient, care partner, friend, or family member looking for available research studies, you can begin to research and identify them on ClinicalTrials.gov.

Research studies give patients an opportunity to participate in research that is either observational, meaning that there is no study drug involved, or to receive an investigational study drug to determine if the drug is safe and effective. Whether you want to participate in any type of MSA research, or you know the study you would like to participate in, you can use ClinicalTrials.gov to learn more about what investigational drugs are being studied, whether clinical trials are open and available for enrollment, and the eligibility criteria. You may also find the contact information for the sites conducting the studies.

This How-To guide will take you through the process of using ClinicalTrials.gov website to find any MSA research study you may be looking for.

# Conducting a Search

Use the ClinicalTrials.gov search function to start researching available studies.

- Populate the fields that apply to your search, such as multiple system atrophy/MSA, the name of a specific drug, or location (start with selecting country, then more choices will appear, and you'll have the option to add details like distance from a particular city).
- Filling in more fields will narrow your search results. For example, if the patient has MSA and is looking for studies involving an investigational drug, completing these fields in the search form will only result in study records that meet both criteria.
- You can also expand or narrow search results by using capitalized operators such as AND, OR, and NOT to relate terms.


**NH** National Library of Medicine  
National Center for Biotechnology Information

PRS Login

**ClinicalTrials.gov** [Go to the classic website](#)

About This Site ▾ Find Studies ▾ Data About Studies ▾ Study Basics ▾ PRS Info ▾ [My Saved Studies \(0\)](#) →

ClinicalTrials.gov is a place to learn about clinical studies from around the world.

 **The U.S. government does not review or approve the safety and science of all studies listed on this website.** +  
Read our full [disclaimer](#) for details.

**Focus Your Search** (all filters optional)

**Condition/disease** ⓘ  
Multiple System Atrophy ..

**Other terms** ⓘ  
MSA - Multiple System Atrophy

**Intervention/treatment** ⓘ  
[Empty text box]

**Location**  
Search by address, city, state, or country and select from the dropdown list  
[Empty text box]

**Study Status** ⓘ  
 All studies  
 Recruiting and not yet recruiting studies

**More Filters** +

**Search**

## Advancing Your Search

By clicking “More Filters”, additional options will open to focus your results even further with criteria such as recruitment status, location, eligibility information, and study type. For example (shown in the image below), if you would only like to view studies recruiting females age 18-64 for a phase 2 interventional trial, then use the options under “More Filters” to fill these fields and find results specific to these criteria.

**More Filters**

**Eligibility Criteria**

**Sex**

All

Female

Male

**Age**

Select ranges

Child (birth - 17)

Adult (18 - 64)

Older adult (65+)

Manually enter range

From  Years Old  To  Years Old

**Accepts healthy volunteers**

Yes

**Study Phase**

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not applicable

**Study Type**

Interventional

Observational

Patient registries

**Search**

# Reading Your Search Results

Once you have conducted your initial search, a list of studies will appear with the most relevant at the top of the page. Search results will show:

- How many studies match your search results
- Study status - active, completed, recruiting, not recruiting, etc
- Study NCT Number - The National Clinical Trial number is an identification that ClinicalTrials.gov assigns a study when it is registered. Until an NCT number is assigned, the study is not registered.
- The name of the study
- The conditions the study is being conducted in
- Locations where the study is being conducted

**Focus Your Search** (all filters optional) Hide

**Condition/disease** +

Multiple System Atrophy

**Other terms** +

**Intervention/treatment** +

**Location**

Search by address, city, state, or country and select from the dropdown list

**Study Status** +

**Looking for participants**

Not yet recruiting (2)

Recruiting (17)

**No longer looking for participants**

Active, not recruiting (5)

Completed (29)

Terminated (3)

**Other**

Enrolling by invitation (0)

Suspended (0)

Withdrawn (2)

Unknown (5)

[Clear Filters \(4\)](#) [Apply Filters](#)

**Search Results** Card View Table View

Viewing 1-10 out of 63 studies

[+ Synonyms of conditions or disease \(8\)](#)

None Selected Download Bookmark RSS

**RECRUITING**

**NCT05109091**

**Study of ATH434 in Participants With Multiple System Atrophy**

Conditions

**Multiple System Atrophy**

Locations

La Jolla, California, United States | Gainesville, Florida, United States

Chicago, Illinois, United States | Glenview, Illinois, United States

[Show 27 more locations](#)

**RECRUITING**

**NCT05698017**

**Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early- to Moderate Stage MSA**

Conditions

**Multiple System Atrophy** **MSA - Multiple System Atrophy**

Locations

Tel Aviv, Israel


**ACTIVE, NOT RECRUITING**

**NCT05104476**

**A Study of Lu AF82422 in Participants With Multiple System Atrophy**

# Modifying Your Search

Depending on how detailed your search criteria is, the results list may provide many studies. If you want to make changes to your search criteria to find studies best suited for the patient and their care partner(s), you can do so using the “Focus Your Search” bar on the left side of the screen.

 **The U.S. government does not review or approve the safety and science of all studies listed on this website.** +  
Read our full [disclaimer](#) for details.

### Focus Your Search

(all filters optional)

**Condition/disease**

**Other terms**

**Intervention/treatment**

**Location**

Search by address, city, state, or country and select from the dropdown list

**Study Status**

**Looking for participants**

Not yet recruiting (1)

Recruiting (8)

**No longer looking for participants**

Active, not recruiting (2)

Completed (12)

Terminated (3)

**Other**

Enrolling by invitation (0)

## Search Results

Viewing 1-10 out of 29 studies

[+ Synonyms of conditions or disease \(7\)](#)

COMPLETED [WITH RESULTS](#)

**NCT00750867**

### Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins

Conditions

Multiple System Atrophy

Locations

Worcester, Massachusetts, United States

COMPLETED [WITH RESULTS](#)

**NCT03753763**

### Safinamide for Multiple System Atrophy (MSA)

Conditions

Multiple System Atrophy

Locations

Bologna, Italy

Brescia, Italy

Cassino, Italy

Chieti, Italy

[Show 19 more locations](#)

UNKNOWN STATUS

HOW TO USE CLINICALTRIALS.GOV

5

# Selecting a Study

For more information regarding a specific study, click on the study name.

**Focus Your Search**  
(all filters optional) Hide

**Condition/disease**  
Multiple System Atrophy

**Other terms**

**Intervention/treatment**

**Location**  
Search by address, city, state, or country and select from the dropdown list

**Study Status**

**Looking for participants**

- Not yet recruiting (2)
- Recruiting (17)

**No longer looking for participants**

- Active, not recruiting (5)
- Completed (29)
- Terminated (3)

**Other**

- Enrolling by invitation (0)
- Suspended (0)
- Withdrawn (2)
- Unknown (5)

[Clear Filters \(4\)](#) [Apply Filters](#)

**Search Results**  
Viewing 1-10 out of 63 studies

[+ Synonyms of conditions or disease \(8\)](#)

None Selected Download Bookmark RSS

**RECRUITING**  
NCT05109091  
**Study of ATH434 in Participants With Multiple System Atrophy**

Conditions  
**Multiple System Atrophy**

Locations  
La Jolla, California, United States  
Chicago, Illinois, United States  
Gainesville, Florida, United States  
Glenview, Illinois, United States  
[Show 27 more locations](#)

**RECRUITING**  
NCT05698017  
**Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early- to Moderate Stage MSA**

Conditions  
**Multiple System Atrophy** **MSA - Multiple System Atrophy**

Locations  
Tel Aviv, Israel

**ACTIVE, NOT RECRUITING**  
NCT05104476  
**A Study of Lu AF82422 in Participants With Multiple System Atrophy**

# Study Record Page

A new page will open with all the details of the selected study. From this overview, you can find the study's start date, their goal completion date, the total number of patients they plan to enroll, the type of study, and its phase.

You can also find the study's sponsor (if applicable), and when the most recent study update was provided.

**RECRUITING** ⓘ

## Study of ATH434 in Participants With Multiple System Atrophy

ClinicalTrials.gov ID ⓘ NCT05109091

Sponsor ⓘ Alterity Therapeutics ←

Information provided by ⓘ Alterity Therapeutics (Responsible Party)

Last Update Posted ⓘ 2023-09-13 ←

Download | Share | + Expand all content | - Collapse all content

**Study Details** | Table View | No Results Posted | Record History

On this page

- Study Overview
- Contacts and Locations
- Participation Criteria
- Study Plan
- Collaborators and Investigators
- Publications
- Study Record Dates
- More Information

### Study Overview

**Brief Summary**  
This study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy

**Official Title**  
A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in **Multiple System Atrophy**

**Conditions** ⓘ  
**Multiple System Atrophy**

**Intervention / Treatment** ⓘ

- Drug: ATH434 dose level 1
- Drug: ATH434 dose level 2
- Drug: Placebo

**Other Study ID Numbers** ⓘ

- ATH434-201

**Study Start (Actual)** ⓘ ←  
2022-07-01

**Primary Completion (Estimated)** ⓘ ←  
2024-06

**Study Completion (Estimated)** ⓘ ←  
2024-07

**Enrollment (Estimated)** ⓘ ←  
60

**Study Type** ⓘ ←  
Interventional

**Phase** ⓘ ←  
Phase 2

Resource links provided by the National Library of Medicine +

### Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

**Study Contact** ⓘ

**Name:** Alterity Clinical Trials  
**Phone Number:**  
+1 650 300-2141

Feedback

This page also allows you to navigate through all study details such as:

- Study contact information
- Study site locations and their contact information
- Criteria to participate in the study
- The study's plan, such as how it has been designed and what it is measuring
- People and organizations that may be collaborating with or involved in the study
- Publications of study results
- Study record dates to include progress of the study and results
- More information that may be helpful to understand the study (terms, helpful links, or study documents).

RECRUITING ⓘ

### Study of ATH434 in Participants With Multiple System Atrophy

ClinicalTrials.gov ID ⓘ NCT05109091

Sponsor ⓘ Alterity Therapeutics

Information provided by ⓘ Alterity Therapeutics (Responsible Party)

Last Update Posted ⓘ 2023-09-13



+ Expand all content

— Collapse all content

#### Study Details

Table View

No Results Posted

Record History

On this page

Study Overview

Contacts and Locations

Participation Criteria

Study Plan

Collaborators and Investigators

Publications

Study Record Dates

More Information

#### Study Overview

Brief Summary

This study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy

Official Title

A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy

Conditions ⓘ

Multiple System Atrophy

Intervention / Treatment ⓘ

- Drug: ATH434 dose level 1
- Drug: ATH434 dose level 2
- Drug: Placebo

Other Study ID Numbers ⓘ

- ATH434-201

Study Start (Actual) ⓘ

2022-07-01

Primary Completion (Estimated) ⓘ

2024-06

Study Completion (Estimated) ⓘ

2024-07

Enrollment (Estimated) ⓘ

60

Study Type ⓘ

Interventional

Phase ⓘ

Phase 2

Resource links provided by the National Library of Medicine



+



# Study Contacts and Site Locations

The Contacts and Locations section provides the contact details for those

**On this page**

- Study Overview
- Contacts and Locations**
- Participation Criteria
- Study Plan
- Collaborators and Investigators
- Publications
- Study Record Dates
- More Information

## Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

**Study Contact**

**Name:** Alterity Clinical Trials  
**Phone Number:** +1 650 300-2141  
**Email:** [ClinicalTrials@alteritytherapeutics.com](mailto:ClinicalTrials@alteritytherapeutics.com)

### United States


California Locations

- La Jolla, California, United States, 92099**  
Recruiting  
University of California San Diego

Florida Locations

- Gainesville, Florida, United States, 32638**  
Recruiting  
University of Florida

Illinois Locations



conducting the study, and information on where the study is being conducted.

## Study Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are:

- Age
- Sex
- How long the participant has had the disease
- If a participant has specific symptoms of the disease being researched
- When symptoms started
- If the participant is a healthy control with no symptoms or disease diagnosis
- A person's general health condition or prior treatments

Researchers also include exclusion criteria, which means that a participant may have characteristics that disqualify them from a study. A participant could be disqualified either by

**On this page**

- Study Overview
- Contacts and Locations
- Participation Criteria**
- Study Plan
- Collaborators and Investigators
- Publications
- Study Record Dates
- More Information

### Participation Criteria

Researchers look for people who fit a certain description, called [eligibility criteria](#). Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read [Learn About Studies](#).

Eligibility Criteria	
Description	Ages Eligible for Study
Inclusion Criteria:	30 Years to 75 Years (Adult, Older Adult)
<ol style="list-style-type: none"><li>1. Participant has clinical features of parkinsonism.</li><li>2. Participant has evidence of orthostatic hypotension and/or bladder dysfunction.</li><li>3. Participant has ataxia and/or pyramidal signs on neurological examination.</li><li>4. Participant is ambulatory.</li><li>5. Participant has biomarker evidence of MSA in biologic fluid and on MRI.</li></ol>	Sexes Eligible for Study
Exclusion Criteria:	All
<ol style="list-style-type: none"><li>1. Participant has motor symptoms for &gt; 4 years.</li><li>2. Participant has advanced disease, as indicated by frequent falls or choking.</li><li>3. Participant has structural brain abnormality on MRI.</li><li>4. Participant has any significant neurological disorder other than MSA.</li><li>5. Participant has an unstable medical or psychiatric illness.</li><li>6. Participant has a contraindication to, or is unable to tolerate, MRI or lumbar puncture.</li></ol>	Accepts Healthy Volunteers
	No

[— Show less](#)

meeting one or more of the exclusion criteria, or not meeting one or more of the inclusion criteria.

## Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring (also known as outcomes or endpoints). Each study evaluates different things, and this section can help explain study components such as:

- A basic description of participant demographics for each group (or cohort) the study is being conducted in
- The intervention or treatment being used in each group
- A brief description of how participants are being evaluated during the study
- What the researchers are using to evaluate a drug or other characteristics of a disease

**Study Plan**  
This section provides details of the study plan, including how the study is designed and what the study is measuring. [Expand all / Collapse all](#)

### How is the study designed?

**Design Details**

**Observational Model** ● : Cohort  
**Time Perspective:** Prospective

Cohorts and Interventions

Group/Cohort ●	Intervention/Treatment ●
<b>Parkinson Disease</b> Patients affected by Parkinson's disease admitted for rehabilitation in Maugeri Clinical Scientific Institutes	<b>Other: Rehabilitation</b> <ul style="list-style-type: none"><li>• All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.</li></ul> <b>Other: Administration of Clinical scales</b> <ul style="list-style-type: none"><li>• All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.</li></ul>
<b>Multiple System Atrophy</b> Patients affected by Multiple System Atrophy admitted for rehabilitation in Maugeri Clinical Scientific Institutes	<b>Other: Rehabilitation</b> <ul style="list-style-type: none"><li>• All patients included in the study will undergo a basic evaluation with a neurological examination, a rehabilitation program to improve strength, coordination, balance, endurance, and the ability to perform activities of daily life.</li></ul> <b>Other: Administration of Clinical scales</b> <ul style="list-style-type: none"><li>• All patients included in the study will be evaluated by clinical scales assessing the disease stage, clinical severity, freezing, motor and non-motor impairment, cognitive impairment, depression, quality of life, autonomic dysfunction, pain.</li></ul>

# Study Plan

## On this page

[Study Overview](#)

[Contacts and Locations](#)

[Participation Criteria](#)

**[Study Plan](#)**

[Collaborators and Investigators](#)

[Publications](#)

[Study Record Dates](#)

[More Information](#)

## Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

[Expand all](#) / [Collapse all](#)

How is the study designed? +

**What is the study measuring?** -

### Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence and Characterization of Pain	Evaluate the prevalence of pain and characterize it in Parkinson's disease and atypical parkinsonisms through KING'S PAIN score	At the recruitment
Prevalence and Characterization of Pain	Evaluate the prevalence of pain and characterize it in Parkinson's disease and atypical parkinsonisms through KING'S PAIN score	At the end of the rehabilitation program, an average of 30 days

### Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Autonomic symptoms	Evaluate the prevalence of autonomic symptoms in Parkinson's disease and atypical parkinsonisms through the score of SCOPA-AUT questionnaire	At the recruitment
Autonomic symptoms	Evaluate the prevalence of autonomic symptoms in Parkinson's disease and atypical parkinsonisms through the score of SCOPA-AUT questionnaire	At the end of the rehabilitation program, an average of 30 days

- How an intervention or the progression of a disease compares to a healthy participant

## Collaborators and Investigators

This section provides information on the people and organizations involved in the study, such as:

- The study's sponsor, which is the organization or person who initiates the study and who has authority and control over the study
- The study's collaborators, which may be an organization or person other than the sponsor that provides support for a study including but not limited

**On this page**

- Study Overview
- Contacts and Locations
- Participation Criteria
- Study Plan
- Collaborators and Investigators**
- Publications
- Study Record Dates
- More Information

### Collaborators and Investigators

This is where you will find people and organizations involved with this study.

**Sponsor** ⓘ ←

**Istituti Clinici Scientifici Maugeri SpA**

**Collaborators** ⓘ ←

No information provided

**Investigators** ⓘ ←

- Principal Investigator: Maria Nolano, MD, PhD, Istituti Clinici Scientifici Maugeri SpA SB - IRCCS of Telese Terme

to funding, design, implementation, data analysis, or reporting.

- The study's investigator(s), who are the researcher(s) involved in conducting the study at a study site. These researchers may also be called principal investigators (PIs) or sub-investigators (sub-I's).

## Publications

This section includes publications that are submitted voluntarily by those conducting the study. These publications may not be related to the study, but rather:

- The study's investigators

**On this page**

- Study Overview
- Contacts and Locations
- Participation Criteria
- Study Plan
- Collaborators and Investigators
- Publications**
- Study Record Dates
- More Information

### Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

#### General Publications

- [Bakkers M, Faber CG, Hooijmakers JG, Lauria G, Merkies IS. Small fibers, large impact: quality of life in small-fiber neuropathy. Muscle Nerve. 2014 Mar;49\(3\):329-36. doi: 10.1002/mus.23910. Epub 2013 Jun 28. ↗](#)
- [Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson's disease: a controlled cross-sectional study. Parkinsonism Relat Disord. 2004 Mar;10\(3\):129-36. doi: 10.1016/j.parkreidis.2003.12.001. ↗](#)
- [Vajlkovic P, Minar M, Sinqliarova H, Harsany J, Hanakova M, Martinkova J, Benetin J. Pain in Parkinson's Disease: A Cross-Sectional Study of Its Prevalence, Types, and Relationship to Depression and Quality of Life. PLoS One. 2015 Aug 26;10\(8\):e0136541. doi: 10.1371/journal.pone.0136541. eCollection 2015. ↗](#)
- [Nolano M, Provitera V, Estraneo A, Selim MM, Caporaso G, Stancanelli A, Saltalamacchia AM, Lanzillo B, Santoro L. Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. Brain. 2008 Jul;131\(Pt 7\):1903-11. doi: 10.1093/brain/awn102. Epub 2008 May 31. ↗](#)
- [Asahina M, Vichayanrat E, Low DA, Iodice V, Mathias CJ. Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology. J Neurol Neurosurg Psychiatry. 2013 Jun;84\(6\):674-80. doi: 10.1136/jnnp-2012-303135. Epub 2012 Sep 1. ↗](#)
- [Linder J, Stenlund H, Forsgren L. Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study. Mov Disord. 2010 Feb 15;25\(3\):341-8. doi: 10.1002/mds.22987. ↗](#)
- [Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, Carroll C, Paviour D, Falup-Pecurariu C, Kessel B, Silverdale M, Todorova A, Sauerbier A, Odin P, Antonini A, Martinez-Martin P, EUROPAR and the IPMDS Non Motor PD Study Group. King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. Mov Disord. 2015 Oct 30;12\(16\):23-31. doi: 10.1002/mds.26270. Epub 2015 Jun 11. ↗](#)

\* Find [Publications about Study Results](#) and related [Pubmed Publications](#) in the "Results" section of the study record.

- The field of study
- Other studies that have been conducted that are relative to this study

Some studies will have publications about study results linked at the bottom of this section.

**On this page**

- Study Overview
- Contacts and Locations
- Participation Criteria
- Study Plan
- Collaborators and Investigators
- Publications
- Study Record Dates**
- More Information

### Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Study Record Updates
<b>First Submitted</b> ⓘ 2023-01-26	<b>Last Update Submitted that met QC Criteria</b> ⓘ ← 2023-02-17
<b>First Submitted that Met QC Criteria</b> ⓘ ←	<b>Last Update Posted</b> ⓘ ← 2023-02-28
<b>First Posted</b> ⓘ 2023-02-28	<b>Last Verified</b> ⓘ ← 2023-01

# Study Record Dates

This section tracks the progress of study records and results, including when this progress was verified. Study records and results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

## More Info

This section provides information about the study, such as the data they collected and the information in

On this page

- Study Overview
- Contacts and Locations
- Participation Criteria
- Study Plan
- Collaborators and Investigators
- Publications
- Study Record Dates
- More Information**

**More Information**

**Record History**

[Expand all / Collapse all](#)

- Terms related to this study +
- Plan for Individual Participant Data (IPD) +
- Drug and device information, study documents, and helpful links +

On this page

- Study Overview
- Contacts and Locations
- Participation Criteria
- Study Plan
- Collaborators and Investigators
- Publications
- Study Record Dates
- More Information**

**More Information**

**Record History**

[Expand all / Collapse all](#)

**Terms related to this study** -

Keywords Provided by Istituto Clinici Scientifici Maugeri SpA	Additional Relevant MeSH Terms
pain	Basal Ganglia Diseases
autonomic symptoms	Brain Diseases
rehabilitation	Central Nervous System Diseases
	Nervous System Diseases
	Movement Disorders
	Synucleinopathies
	Neurodegenerative Diseases
	Primary Dysautonomias
	Autonomic Nervous System Diseases
	Hypotension
	Vascular Diseases
	Cardiovascular Diseases
	Parkinson Disease
	Multiple System Atrophy
	Shy-Drager Syndrome
	Parkinsonian Disorders

- Plan for Individual Participant Data (IPD) +
- Drug and device information, study documents, and helpful links +